From the Journals

This Week’s Biopharma News: New Pharma Legislation in Europe

Our latest news roundup reports on the oversubscribed financing for Cellular Origins, FDA approval for Amgen, CAR-T cell therapy outcomes, and more

  • December 16, 2025

  • 6 min

Share

5 Key Takeaways

  • 1

    EU pharmaceutical legislation reform aims to modernize processes and enhance access.

  • 2

    Waskyra is the first FDA-approved gene therapy for Wiskott–Aldrich syndrome.

  • 3

    Moderna licenses drug delivery technology from Nanexa.

  • 4

    Uplizna approved for generalized myasthenia gravis treatment.

  • 5

    Patient remains disease-free five years post CAR T cell therapy.

Related Content

Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min
Dana-Farber Research Supports FDA Approval of T-DXd Plus Pertuzumab for First-Line Treatment of HER2+ Metastatic Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer.

  • by

  • December 15, 2025

  • 2 min
Dana-Farber researchers present findings at 2025 San Antonio Breast Cancer Symposium

Physician scientists from Dana-Farber Cancer Institute will present more than 50 research studies at the 48th annual San Antonio Breast Cancer Symposium, December 9-12.

  • by

  • December 4, 2025

  • 7 min